NASDAQ:ADXSAdvaxis Stock Price, Forecast & News

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ADXS shares have increased by 13.7% and is now trading at $0.7577. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Advaxis.

Advaxis is scheduled to release its next quarterly earnings announcement on Thursday, June 11th 2020. View our earnings forecast for Advaxis.

Advaxis will be holding an earnings conference call on Thursday, June 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Advaxis, Inc. (NASDAQ:ADXS) released its earnings results on Friday, March, 13th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. Advaxis had a negative return on equity of 82.13% and a negative net margin of 3,108.18%. View Advaxis' earnings history.

Headlines about ADXS stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Advaxis earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutAdvaxis.

Some companies that are related to Advaxis include Nature's Sunshine Products (NATR), TAIWAN LIPOSOME/S (TLC), Five Prime Therapeutics (FPRX), NeuBase Therapeutics (NBSE), Aquestive Therapeutics (AQST), Scpharmaceuticals (SCPH), IDEAYA Biosciences (IDYA), Strongbridge Biopharma (SBBP), Aytu Bioscience (AYTU), Xeris Pharmaceuticals (XERS), Tyme Technologies (TYME), Cerecor (CERC), CELYAD SA/ADR (CYAD), Evolus (EOLS) and Tiziana Life Sciences (TLSA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Anavex Life Sciences (AVXL), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Novavax (NVAX) and Opko Health (OPK).

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Advaxis' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.41%) and Private Advisor Group LLC (0.33%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel. View institutional ownership trends for Advaxis.

ADXS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., and Private Advisor Group LLC. View insider buying and selling activity for Advaxis.

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ADXS stock can currently be purchased for approximately $0.76.

Advaxis has a market capitalization of $45.65 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe.

The official website for Advaxis is www.advaxis.com.

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]